Search

Author/Creator McGarry, Lisa J.

1. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison. (4th March 2019)

Authors:
Levy, Moshe Yair; McGarry, Lisa J.; Huang, Hui; Lustgarten, Stephanie; Chiroli, Silvia; Iannazzo, Sergio
Journal:
Current medical research and opinion
Issue:
Volume 35:Number 3(2019)
Page Start:
479
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. (1st February 2016)

Authors:
McGarry, Lisa J.; Chen, Yaozhu J.; Divino, Victoria; Pokras, Shibani; Taylor, Catherine R.; Munakata, Julie; Nieset, Christopher C.; Huang, Hui; Jabbour, Elias; Malone, Daniel C.
Journal:
Current medical research and opinion
Issue:
Volume 32:Number 2(2016:Feb.)
Page Start:
289
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation. Issue 15 (7th April 2017)

Authors:
Nicolini, Franck E.; Basak, Grzegorz W.; Kim, Dong‐Wook; Olavarria, Eduardo; Pinilla‐Ibarz, Javier; Apperley, Jane F.; Hughes, Timothy; Niederwieser, Dietger; Mauro, Michael J.; Chuah, Charles; Hochhaus, Andreas; Martinelli, Giovanni; DerSarkissian, Maral; Duh, Mei Sheng; McGarry, Lisa J.; Kantar...
Journal:
Cancer
Issue:
Volume 123:Issue 15(2017)
Page Start:
2875
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗